tradingkey.logo
tradingkey.logo
Search

Grail Inc

GRAL
Add to Watchlist
61.260USD
-0.380-0.62%
Close 05/11, 16:00ETQuotes delayed by 15 min
2.52BMarket Cap
LossP/E TTM
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-0.62%

5 Days

+13.32%

1 Month

+34.25%

6 Months

-28.02%

Year to Date

-28.43%

1 Year

+74.03%

TradingKey Stock Score of Grail Inc

Currency: USD Updated: 2026-05-08

Key Insights

Grail Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 67.71.In the medium term, the stock price is expected to trend down.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Grail Inc's Score

Industry at a Glance

Industry Ranking
33 / 384
Overall Ranking
129 / 4494
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Grail Inc Highlights

StrengthsRisks
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 58.07% year-on-year.
Undervalued
The company’s latest PE is -5.55, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 30.84M shares, decreasing 3.31% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 5.24K shares of this stock.

Analyst Rating

Based on 8 analysts
Buy
Current Rating
66.857
Target Price
+8.46%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Grail Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Grail Inc Info

Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
Ticker SymbolGRAL
CompanyGrail Inc
CEORagusa (Robert)
Websitehttps://grail.com/
KeyAI